Orchestra BioMed
OBIO
52 hedge funds and large institutions have $56.1M invested in Orchestra BioMed in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 17 closing their positions.
18% more capital invested
Capital invested by funds: $47.6M → $56.1M (+$8.54M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.91% less ownership
Funds ownership: 47.33% → 42.42% (-4.9%)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
12% less funds holding
Funds holding: 59 → 52 (-7)
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
82% less call options, than puts
Call options by funds: $27K | Put options by funds: $149K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.77M |
| 2 |
Pathstone Holdings
Englewood,
New Jersey
|
+$2.78M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$2.01M |
| 4 |
PA
Perceptive Advisors
New York
|
+$1.93M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$202K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$133K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$133K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$122K |
| 5 |
Millennium Management
New York
|
-$98.5K |
OBIO Hedge Fund Activity: Q3 2025 in Review
52 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q3 2025, worth a combined $56.1M — up 18% from $47.6M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of OBIO and 10 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $3.77M. The largest seller was Goldman Sachs, cutting an estimated $202K.
- 52 institutional investors held Orchestra BioMed (OBIO) as of Q3 2025, down from 59 in Q2 2025.
- Funds reported $56.1M of Orchestra BioMed stock for Q3 2025, up 18% quarter-over-quarter.
- 10 funds opened new Orchestra BioMed positions in Q3 2025 and 17 closed out, a net change of -7 holders.
- The largest Orchestra BioMed buyer in Q3 2025 was Alyeska Investment Group, an estimated $3.77M added.
- The largest Orchestra BioMed seller in Q3 2025 was Goldman Sachs, an estimated $202K sold.
Based on aggregated 13F filings for Q3 2025.